CGEN Compugen Ltd.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

$4.43  -0.04 (-0.90%)
As of 11/30/2021 15:59:34 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  Israel
IPO date:  02/12/2001
Outstanding shares:  83,917,929
Average volume:  2,015,214
Market cap:   $380,987,398
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    M25722105
ISIN:        IL0010852080
Sedol:      2620859
Valuation   (See tab for details)
PE ratio:   -25.49
PB ratio:   3.80
PS ratio:   47.62
Return on equity:   -34.53%
Net income %:   -426.51%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy